Payment overview · 2025
General Payments
$285.62
16 reported records · 9 companies
Healthcare provider profile · identity verified
John R Shell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BURLINGTON, KS · NPI 1366446221
Verified facts
What the public records show
CMS Open Payments records show John R Shell, M.D. received $285.62 in general payments during 2025 across 16 reported records.
Dexcom, Inc. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.96 | 15.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.45 | 15.6% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $36.17 | 12.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.65 | 12.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.53 | 11.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.66 | 11.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.54 | 8.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.73 | 6.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.93 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $285.62 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44.45 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $36.17 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.66 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.66 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 614 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 608 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 466 | 99 |
| Lisinopril | Lisinopril | 434 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 415 | 82 |
| Potassium Chloride | Potassium Chloride | 379 | 76 |
| Simvastatin | Simvastatin | 328 | 61 |
| Omeprazole | Omeprazole | 322 | 60 |
| Gabapentin | Gabapentin | 295 | 50 |
| Metformin Hcl | Metformin Hcl | 268 | 46 |
| Furosemide | Furosemide | 247 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 48 |
| Prednisone | Prednisone | 239 | 163 |
| Eliquis | Apixaban | 237 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 236 | 56 |
| Sertraline Hcl | Sertraline Hcl | 220 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 206 | 21 |
| Alprazolam | Alprazolam | 192 | 33 |
| Carvedilol | Carvedilol | 191 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 175 | 35 |
| Losartan Potassium | Losartan Potassium | 169 | 38 |
| Clonazepam | Clonazepam | 168 | 27 |
| Meloxicam | Meloxicam | 141 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 23 |
| Glimepiride | Glimepiride | 131 | 26 |
| Levetiracetam | Levetiracetam | 119 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 110 | 21 |
| Alendronate Sodium | Alendronate Sodium | 107 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | 16 |
| Topiramate | Topiramate | 93 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 92 | 20 |
| Warfarin Sodium | Warfarin Sodium | 89 | 13 |
| Ezetimibe | Ezetimibe | 87 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 84 | 13 |
| Aripiprazole | Aripiprazole | 80 | 11 |
| Ketoconazole | Ketoconazole | 76 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 17 |
| Azithromycin | Azithromycin | 75 | 56 |
| Temazepam | Temazepam | 73 | 17 |
| Montelukast Sodium | Montelukast Sodium | 71 | 12 |
| Tramadol Hcl | Tramadol Hcl | 71 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 15 |
| Allopurinol | Allopurinol | 68 | 15 |
| Clonidine Hcl | Clonidine Hcl | 67 | 14 |
| Olanzapine | Olanzapine | 66 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 12 |
| Baclofen | Baclofen | 61 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 11 |
| Trazodone Hcl | Trazodone Hcl | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 15 |
| Lorazepam | Lorazepam | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | 12 |
| Donepezil Hcl | Donepezil Hcl | 52 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | suppressed |
| Estradiol | Estradiol | 51 | 12 |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | suppressed |
| Celecoxib | Celecoxib | 50 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 13 |
| Cephalexin | Cephalexin | 45 | 30 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Risperidone | Risperidone | 44 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 19 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 36 |
| Ozempic | Semaglutide | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 17 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Nystatin | Nystatin | 25 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Bumetanide | Bumetanide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 21 | 11 |
| Fentanyl | Fentanyl | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Pancreaze | Lipase/Protease/Amylase | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Vardenafil Hcl | Vardenafil Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $285.62 · 16 records | Dexcom, Inc. | Auvelity, CAPVAXIVE, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, UBRELVY, Wegovy, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error